The functional loss of CDKN2A is linked to dysregulated P53 expression leading to more aggressive lymphomagenesis and worse clinical outcome in DLBCL, despite standard chemotherapy [28,29,30,31,32,33]. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.